by Truveta staff | Aug 25, 2025 | Research
Multiple sclerosis (MS) affects approximately 1 million people in the United States, with women representing nearly 75% of patients. Over the past decade, consensus guidelines from leading MS experts have increasingly emphasized the importance of early intervention...
by Truveta Research | Aug 22, 2025 | Research, Research Insights
Authors: Mantas Dmukauskas, PhD ⊕Truveta, Inc, Bellevue, WA, Sarah Blach, MS ⊕Truveta, Inc, Bellevue, WA, Sunny Guin, PhD ⊕Truveta, Inc, Bellevue, WA, Amy Wu ⊕Truveta, Inc, Bellevue, WA The survival rate for patients with glioblastoma (GBM) differs significantly by...
by Truveta Research | Aug 22, 2025 | Research, Research Insights
Authors: Katie Kendrick, MPH ⊕Truveta, Inc, Bellevue, WA, Amy Sullivan, MS ⊕Truveta, Inc, Bellevue, WA, Sunny Guin, PhD ⊕Truveta, Inc, Bellevue, WA, Agnes Pastwa ⊕Truveta, Inc, Bellevue, WA, Sarah Platt, MS ⊕Truveta, Inc, Bellevue, WA Truveta Data is well-suited to...
by Truveta Research | Aug 22, 2025 | Research, Research Insights
Authors: Katie Kendrick, MPH ⊕Truveta, Inc, Bellevue, WA, Amy Sullivan, MS ⊕Truveta, Inc, Bellevue, WA, Sunny Guin, PhD ⊕Truveta, Inc, Bellevue, WA, Agnes Pastwa ⊕Truveta, Inc, Bellevue, WA, Sarah Platt, MS ⊕Truveta, Inc, Bellevue, WA Truveta Data is well-suited to...
by Truveta Research | Aug 22, 2025 | Research, Research Insights
Authors: Amy Austin, MS ⊕Truveta, Inc, Bellevue, WA, Emily Webber, PhD ⊕Truveta, Inc, Bellevue, WA, Sarah Blach, MS ⊕Truveta, Inc, Bellevue, WA, Jared Kern ⊕Truveta, Inc, Bellevue, WA, Sarah Platt, MS ⊕Truveta, Inc, Bellevue, WA, Sally Omidvar, MSPH, MS ⊕Truveta, Inc,...
by Truveta staff | Aug 18, 2025 | Research
After years of uncertainty, a recent policy change is sparking new optimism in rare disease drug development. A change in federal policy now keeps certain multi-indication rare therapies exempt from Medicare price negotiations—a rule that had discouraged some...
